Infliximab for the treatment of fistulas in patients with Crohn's disease

Daniel H. Present, Paul Rutgeerts, Stephan Targan, Stephen B. Hanauer, Lloyd Mayer, R. A. Van Hogezand, Daniel K. Podolsky, Bruce E. Sands, Tanja Braakman, Kimberly L. Dewoody, Thomas F. Schaible, Sander J H Van Deventer

Research output: Contribution to journalArticle

2177 Citations (Scopus)

Abstract

Background Enterocutaneous fistulas are a serious complication of Crohn's disease and are difficult to treat. Infliximab, a chimeric monoclonal antibody to tumor necrosis factor α, has recently been developed as a treatment for Crohn's disease. We conducted a randomized, multicenter, double-blind, placebo-controlled trial of infliximab for the treatment of fistulas in patients with Crohn's disease. Methods The study included 94 adult patients who had draining abdominal or perianal fistulas of at least three months' duration as a complication of Crohn's disease. Patients were randomly assigned to receive one of three treatments: placebo (31 patients), 5 mg of infliximab per kilogram of body weight (31 patients), or 10 mg of infliximab per kilogram (32 patients); all three were to be administered intravenously at weeks 0, 2, and 6. The primary end point was a reduction of 50 percent or more from base line in the number of draining fistulas observed at two or more consecutive study visits. A secondary end point was the closure of all fistulas. Results Sixty-eight percent of the patients who received 5 mg of infliximab per kilogram and 56 percent of those who received 10 mg per kilogram achieved the primary end point, as compared with 26 percent of the patients in the placebo group (P=0.002 and P=0.02, respectively). In addition, 55 percent of the patients assigned to receive 5 mg of infliximab per kilogram and 38 percent of those assigned to 10 mg per kilogram had closure of all fistulas, as compared with 13 percent of the patients assigned to placebo (P=0.001 and P=0.04, respectively). The median length of time during which the fistulas remained closed was three months. More than 60 percent of patients in all the groups had adverse events. For patients treated with infliximab, the most common were headache, abscess, upper respiratory tract infection, and fatigue. Conclusions Infliximab is an efficacious treatment for fistulas in patients with Crohn's disease.

Original languageEnglish (US)
Pages (from-to)1398-1405
Number of pages8
JournalNew England Journal of Medicine
Volume340
Issue number18
DOIs
StatePublished - May 6 1999

Fingerprint

Crohn Disease
Fistula
Therapeutics
Placebos
Infliximab
Intestinal Fistula
Respiratory Tract Infections
Abscess
Fatigue
Headache
Tumor Necrosis Factor-alpha
Monoclonal Antibodies
Body Weight

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Present, D. H., Rutgeerts, P., Targan, S., Hanauer, S. B., Mayer, L., Van Hogezand, R. A., ... Van Deventer, S. J. H. (1999). Infliximab for the treatment of fistulas in patients with Crohn's disease. New England Journal of Medicine, 340(18), 1398-1405. https://doi.org/10.1056/NEJM199905063401804

Infliximab for the treatment of fistulas in patients with Crohn's disease. / Present, Daniel H.; Rutgeerts, Paul; Targan, Stephan; Hanauer, Stephen B.; Mayer, Lloyd; Van Hogezand, R. A.; Podolsky, Daniel K.; Sands, Bruce E.; Braakman, Tanja; Dewoody, Kimberly L.; Schaible, Thomas F.; Van Deventer, Sander J H.

In: New England Journal of Medicine, Vol. 340, No. 18, 06.05.1999, p. 1398-1405.

Research output: Contribution to journalArticle

Present, DH, Rutgeerts, P, Targan, S, Hanauer, SB, Mayer, L, Van Hogezand, RA, Podolsky, DK, Sands, BE, Braakman, T, Dewoody, KL, Schaible, TF & Van Deventer, SJH 1999, 'Infliximab for the treatment of fistulas in patients with Crohn's disease', New England Journal of Medicine, vol. 340, no. 18, pp. 1398-1405. https://doi.org/10.1056/NEJM199905063401804
Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, Van Hogezand RA et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. New England Journal of Medicine. 1999 May 6;340(18):1398-1405. https://doi.org/10.1056/NEJM199905063401804
Present, Daniel H. ; Rutgeerts, Paul ; Targan, Stephan ; Hanauer, Stephen B. ; Mayer, Lloyd ; Van Hogezand, R. A. ; Podolsky, Daniel K. ; Sands, Bruce E. ; Braakman, Tanja ; Dewoody, Kimberly L. ; Schaible, Thomas F. ; Van Deventer, Sander J H. / Infliximab for the treatment of fistulas in patients with Crohn's disease. In: New England Journal of Medicine. 1999 ; Vol. 340, No. 18. pp. 1398-1405.
@article{6acf394f2e6947cea8e9a0cde413bfbe,
title = "Infliximab for the treatment of fistulas in patients with Crohn's disease",
abstract = "Background Enterocutaneous fistulas are a serious complication of Crohn's disease and are difficult to treat. Infliximab, a chimeric monoclonal antibody to tumor necrosis factor α, has recently been developed as a treatment for Crohn's disease. We conducted a randomized, multicenter, double-blind, placebo-controlled trial of infliximab for the treatment of fistulas in patients with Crohn's disease. Methods The study included 94 adult patients who had draining abdominal or perianal fistulas of at least three months' duration as a complication of Crohn's disease. Patients were randomly assigned to receive one of three treatments: placebo (31 patients), 5 mg of infliximab per kilogram of body weight (31 patients), or 10 mg of infliximab per kilogram (32 patients); all three were to be administered intravenously at weeks 0, 2, and 6. The primary end point was a reduction of 50 percent or more from base line in the number of draining fistulas observed at two or more consecutive study visits. A secondary end point was the closure of all fistulas. Results Sixty-eight percent of the patients who received 5 mg of infliximab per kilogram and 56 percent of those who received 10 mg per kilogram achieved the primary end point, as compared with 26 percent of the patients in the placebo group (P=0.002 and P=0.02, respectively). In addition, 55 percent of the patients assigned to receive 5 mg of infliximab per kilogram and 38 percent of those assigned to 10 mg per kilogram had closure of all fistulas, as compared with 13 percent of the patients assigned to placebo (P=0.001 and P=0.04, respectively). The median length of time during which the fistulas remained closed was three months. More than 60 percent of patients in all the groups had adverse events. For patients treated with infliximab, the most common were headache, abscess, upper respiratory tract infection, and fatigue. Conclusions Infliximab is an efficacious treatment for fistulas in patients with Crohn's disease.",
author = "Present, {Daniel H.} and Paul Rutgeerts and Stephan Targan and Hanauer, {Stephen B.} and Lloyd Mayer and {Van Hogezand}, {R. A.} and Podolsky, {Daniel K.} and Sands, {Bruce E.} and Tanja Braakman and Dewoody, {Kimberly L.} and Schaible, {Thomas F.} and {Van Deventer}, {Sander J H}",
year = "1999",
month = "5",
day = "6",
doi = "10.1056/NEJM199905063401804",
language = "English (US)",
volume = "340",
pages = "1398--1405",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "18",

}

TY - JOUR

T1 - Infliximab for the treatment of fistulas in patients with Crohn's disease

AU - Present, Daniel H.

AU - Rutgeerts, Paul

AU - Targan, Stephan

AU - Hanauer, Stephen B.

AU - Mayer, Lloyd

AU - Van Hogezand, R. A.

AU - Podolsky, Daniel K.

AU - Sands, Bruce E.

AU - Braakman, Tanja

AU - Dewoody, Kimberly L.

AU - Schaible, Thomas F.

AU - Van Deventer, Sander J H

PY - 1999/5/6

Y1 - 1999/5/6

N2 - Background Enterocutaneous fistulas are a serious complication of Crohn's disease and are difficult to treat. Infliximab, a chimeric monoclonal antibody to tumor necrosis factor α, has recently been developed as a treatment for Crohn's disease. We conducted a randomized, multicenter, double-blind, placebo-controlled trial of infliximab for the treatment of fistulas in patients with Crohn's disease. Methods The study included 94 adult patients who had draining abdominal or perianal fistulas of at least three months' duration as a complication of Crohn's disease. Patients were randomly assigned to receive one of three treatments: placebo (31 patients), 5 mg of infliximab per kilogram of body weight (31 patients), or 10 mg of infliximab per kilogram (32 patients); all three were to be administered intravenously at weeks 0, 2, and 6. The primary end point was a reduction of 50 percent or more from base line in the number of draining fistulas observed at two or more consecutive study visits. A secondary end point was the closure of all fistulas. Results Sixty-eight percent of the patients who received 5 mg of infliximab per kilogram and 56 percent of those who received 10 mg per kilogram achieved the primary end point, as compared with 26 percent of the patients in the placebo group (P=0.002 and P=0.02, respectively). In addition, 55 percent of the patients assigned to receive 5 mg of infliximab per kilogram and 38 percent of those assigned to 10 mg per kilogram had closure of all fistulas, as compared with 13 percent of the patients assigned to placebo (P=0.001 and P=0.04, respectively). The median length of time during which the fistulas remained closed was three months. More than 60 percent of patients in all the groups had adverse events. For patients treated with infliximab, the most common were headache, abscess, upper respiratory tract infection, and fatigue. Conclusions Infliximab is an efficacious treatment for fistulas in patients with Crohn's disease.

AB - Background Enterocutaneous fistulas are a serious complication of Crohn's disease and are difficult to treat. Infliximab, a chimeric monoclonal antibody to tumor necrosis factor α, has recently been developed as a treatment for Crohn's disease. We conducted a randomized, multicenter, double-blind, placebo-controlled trial of infliximab for the treatment of fistulas in patients with Crohn's disease. Methods The study included 94 adult patients who had draining abdominal or perianal fistulas of at least three months' duration as a complication of Crohn's disease. Patients were randomly assigned to receive one of three treatments: placebo (31 patients), 5 mg of infliximab per kilogram of body weight (31 patients), or 10 mg of infliximab per kilogram (32 patients); all three were to be administered intravenously at weeks 0, 2, and 6. The primary end point was a reduction of 50 percent or more from base line in the number of draining fistulas observed at two or more consecutive study visits. A secondary end point was the closure of all fistulas. Results Sixty-eight percent of the patients who received 5 mg of infliximab per kilogram and 56 percent of those who received 10 mg per kilogram achieved the primary end point, as compared with 26 percent of the patients in the placebo group (P=0.002 and P=0.02, respectively). In addition, 55 percent of the patients assigned to receive 5 mg of infliximab per kilogram and 38 percent of those assigned to 10 mg per kilogram had closure of all fistulas, as compared with 13 percent of the patients assigned to placebo (P=0.001 and P=0.04, respectively). The median length of time during which the fistulas remained closed was three months. More than 60 percent of patients in all the groups had adverse events. For patients treated with infliximab, the most common were headache, abscess, upper respiratory tract infection, and fatigue. Conclusions Infliximab is an efficacious treatment for fistulas in patients with Crohn's disease.

UR - http://www.scopus.com/inward/record.url?scp=0033529049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033529049&partnerID=8YFLogxK

U2 - 10.1056/NEJM199905063401804

DO - 10.1056/NEJM199905063401804

M3 - Article

C2 - 10228190

AN - SCOPUS:0033529049

VL - 340

SP - 1398

EP - 1405

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 18

ER -